COChe Y. O'MAy

Che Y. O'MAy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Che Y. O'MAy has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions

    by Che Y. O'MAy, Kevin Sanderson, Louise F. Roddam, Sylvia M. Kirov, David W. Reid

    The success of Pseudomonas aeruginosa in cystic fibrosis (CF) and other chronic infections is largely attributed to its ability to grow in antibiotic-resistant biofilm communities. This study investigated the effects of limiting iron levels as a strategy for preventing/disrupting P. aeruginosa biofilms. A range of synthetic and naturally occurring iron-chelating agents were examined. Biofilm development by P. aeruginosa strain PAO1 and CF sputum isolates from chronically infected individuals was significantly decreased by iron removal under aerobic atmospheres. CF strains formed poor biofilms under anaerobic conditions. Strain PAO1 was also tested under anaerobic conditions. Biofilm formation by this model strain was almost totally prevented by several of the chelators tested. The ability of synthetic chelators to impair biofilm formation could be reversed by iron addition to cultures, providing evidence that these effective chelating compounds functioned by directly reducing availability of iron to P. aeruginosa. In contrast, the biological chelator lactoferrin demonstrated enhanced anti-biofilm effects as iron supplementation increased. Hence biofilm inhibition by lactoferrin appeared to occur through more complex mechanisms to those of the synthetic chelators. Overall, our results demonstrate the importance of iron availability to biofilms and that iron chelators have potential as adjunct therapies for preventing biofilm development, especially under low oxygen conditions such as encountered in the chronically infected CF lung.


  • Open Access

    Iron chelation directed against biofilms as an adjunct to conventional antibiotics

    by D. W. Reid, C. O'May, S. M. Kirov, L. Roddam, I. L. Lamont, K. Sanderson

    To the editor: We read with interest the study by Moreau-Marquis et al. demonstrating the bactericidal effect of two iron-chelating compounds directed against Pseudomonas aeruginosa when combined with the aminoglycoside antibiotic tobramycin, following their recent demonstration of abnormal cystic fibrosis epithelial cell iron hardling ([1][1], [2][2]). In similar experiments to those of Moreau-Marquis and colleagues, we assessed the effects of the synthetic iron chelator 2,2-dipyridyl (2DP) on minimal inhibitory concentrations (MICs) of ceftazidime and meropenem. We used a broth microdilution technique in medium containing low (≤1 μM) or high (10 μM) amounts of iron (FeCl3) and examined growth and biofilm formation under aerobic and anaerobic conditions. The inclusion of anaerobic experiments is critical, as these conditions are likely encountered by P. aeruginosa in the cystic fibrosis (CF) lung environment, and anaerobic growth within biofilms is thought to be a critical factor in persistence ([4][3], [5][4]). Our data demonstrate that the iron requirement for growth and biofilm formation is much higher when bacteria are grown anaerobically compared with aerobically (O'May, unpublished observations). Under aerobic conditions, iron had little effect on MICs, but when P. aeruginosa strains were grown anaerobically in the presence of supplemental iron, the MICs were significantly increased to the point where the strains were considered to be resistant. The antimicrobial resistance of strains to ceftazidime and meropenem was significantly decreased (up to 4-fold) under both aerobic and anaerobic growth conditions by the addition of 2DP at levels that did not inhibit P. aeruginosa growth. Interestingly, under anaerobic conditions, the concentration of 2DP required to achieve the same reduction in MIC was much lower than under aerobic conditions. In experiments using a flow cell biofilm model in which bacteria were grown on glass surfaces and stained for viability (live P. aeruginosa stains green and dead bacteria stain red; BacLight), we have demonstrated that a combination of 2DP and tobramycin results in areas of denuded biofilm in close proximity to dead bacteria (see [Fig. 1][5]). In contrast, tobramycin on its own had no effect. The 2DP and tobramycin combination was superior to 2DP alone. We have previously reported, using this model, that 2DP can reduce P. aeruginosa biofilm mass and height, but not bacterial viability or biofilm surface area coverage (chelator added to mature biofilms formed over 2–3 days) (O'May, unpublished observations). Our flow cell experiments imply that iron-chelation disrupts biofilm structure, which then allows antibiotic penetration and bacterial killing. In the flow cell method, biofilms are mature and in their most resistant form when chelator-antibiotic interventions are introduced and complement the results from the model of Moreau-Marquis and colleagues where biofilms were assessed at an early stage of development (≤6 h). Collectively, the data of our studies ([3][6]) and those of Moreau-Marquis et al. ([1][1]) show that combination therapy with iron-chelators and conventional antibiotics may be particularly effective in the CF lung, especially in view of the increased amounts of iron available to support P. aeruginosa replication and biofilm formation in this disease. Our data also suggest that iron chelation may enhance the efficacy of antibiotics such as tobramycin under low oxygen tensions, which normally impair the bactericidal effects of the aminoglycosides. ![Fig. 1.][7] Fig. 1. 2,2-Dipyridyl (2DP, 2,500 μM) was added to the flow cell from day 3 once the biofilm had become established. Flow cells were exposed to tobramycin (100 μg/ml) for 1 h on day 7 and then stained for viability. Five representative panels are shown for each treatment. A : tobramycin alone; B : 2DP alone; C : tobramycin + 2DP. Live bacteria stain green and dead bacteria stain red. Yellow represents regions where both live and dead bacteria are present, and darker areas show where no biofilm is present. The images for control experiments are not shown. 1. [↵][8] Moreau-Marquis S , Bomberger JM, Anderson GG, Swiatecka-Urban A, Ye S, O'Toole GA, Stanton BA. The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 295: L25–L37, 2008. [OpenUrl][9][Abstract/FREE Full Text][10] 2. [↵][11] Moreau-Marquis S , O'Toole GA, Stanton BA. Tobramycin and FDA-approved iron chelators eliminate P. aeruginosa biofilms on cystic fibrosis cells. Am J Respir Cell Mol Biol. In press. 3. [↵][12] Reid DW , Carroll V, O'May C, Champion A, Kirov SM. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. Eur Respir J 30: 286–292, 2007. [OpenUrl][13][Abstract/FREE Full Text][14] 4. [↵][15] Worlitzsch D , Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, Doring G. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109: 317–325, 2002. [OpenUrl][16][CrossRef][17][Medline][18][Web of Science][19] 5. [↵][20] Yoon SS , Hennigan RF, Hilliard GM, Ochsner UA, Parvatiyar K, Kamani MC, Allen HL, DeKievit TR, Gardner PR, Schwab U, Rowe JJ, Iglewski BH, McDermott TR, Mason RP, Wozniak DJ, Hancock RE, Parsek MR, Noah TL, Boucher RC, Hassett DJ. Pseudomonas aeruginosa anaerobic respiration in biofilms: relationships to cystic fibrosis pathogenesis. Dev Cell 3: 593–603, 2002. [OpenUrl][21][CrossRef][22][Medline][23][Web of Science][24] [1]: #ref-1 [2]: #ref-2 [3]: #ref-4 [4]: #ref-5 [5]: #F1 [6]: #ref-3 [7]: pending:yes [8]: #xref-ref-1-1 "View reference 1 in text" [9]:...


  • Biofilm differentiation and dispersal in mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis

    by Sylvia M. Kirov, Jeremy S. Webb, Che Y. O'MAy, David W. Reid, Jerry K. K. Woo, Scott A. Rice, Staffan Kjelleberg

    Intractable biofilm infections with Pseudomonas aeruginosa are the major cause of premature death associated with cystic fibrosis (CF). Few studies have explored the biofilm developmental cycle of P. aeruginosa isolates from chronically infected individuals. This study shows that such clinical isolates exhibit biofilm differentiation and dispersal processes similar to those of the better-studied laboratory P. aeruginosa strain PAO1 in the glass flow-cell (continuous-culture) biofilm model, albeit they are initially less adherent and their microcolonies are slower to develop and show heterogeneous, strain-specific variations in architecture. Confocal scanning laser microscopy combined with LIVE/DEAD viability staining revealed that in all CF biofilms bacterial cell death occurred in maturing biofilms, extending from the substratum to the central regions of mature microcolonies to varying degrees, depending on the strain. Bacteriophage activity was detected in the maturing biofilms of all CF strains examined and the amount of phage produced paralleled the degree of cell death seen in the biofilm. Some CF strains exhibited ‘seeding dispersal’ associated with the above phenomena, producing ‘hollowing’ as motile cells evacuated from the microcolony interiors as has been described for strain PAO1. Moreover, morphotypic cell variants were seen in the biofilm effluents of all CF strains. For those CF strains where marked cell death and seeding dispersal occurred in the microcolonies, variants were more diverse (up to five morphotypes) compared to those of strain PAO1 (two morphotypes). Given that variants of strain PAO1 have enhanced colonization traits, it seems likely that the similar biofilm dispersal events described here for CF strains contribute to the variability seen in clinical isolates and the overall persistence of the P. aeruginosa in the CF airway.


  • Open Access

    Increased airway iron as a potential factor in the persistence ofPseudomonas aeruginosainfection in cystic fibrosis

    by D. W. Reid, V. Carroll, C. O'MAy, A. Champion, S. M. Kirov

    Iron availability is critical to many bacteria and increased iron has been described in airway secretions in cystic fibrosis (CF). The main aim of the present study was to assess the relationship between iron in CF sputum and the quantitative bacterial burden.Iron, ferritin and total cell counts (TCC) were assessed in sputum samples obtained from 15 clinically stable CF patients chronically infected withPseudomonas aeruginosa. Sputum samples were also obtained at the commencement of episodes of acute exacerbation in 10 subjects and analyses were repeated in six of these exacerbation cases afteri.v.antibiotic treatment. The relationship between iron indices and the presence ofP. aeruginosa, as well as total anaerobic bacterial load, was determined. Sputum was also obtained from 10 CF patients with no evidence of infection withP. aeruginosaand 11 normal healthy controls.Sputum iron, ferritin and TCC were significantly elevated in all CF patients, even in those not infected withP. aeruginosa, compared with healthy controls. There was a strong positive relationship between sputum iron andP. aeruginosain clinically stable patients, but not in samples obtained during an acute exacerbation. There was no relationship between sputum iron and anaerobic bacterial load. Antibiotic treatment significantly reduced sputum TCC and anaerobic bacterial load, but not iron, ferritin or the presence ofP. aeruginosaduring an exacerbation.In conclusion, the present study suggests that increased airway iron may be important toPseudomonas aeruginosapersistence in cystic fibrosis.


  • Open Access

    Anaerobic culture conditions favor biofilm-like phenotypes inPseudomonas aeruginosaisolates from patients with cystic fibrosis

    by Che Y. O'May, David W. Reid, Sylvia M. Kirov

    Pseudomonas aeruginosa causes chronic infections in the lungs of cystic fibrosis (CF) individuals and remains the leading cause of morbidity and morta